NEW YORK (GenomeWeb News) – Danish genomics and molecular diagnostics firm Exiqon today reported that its third-quarter revenues rose 11 percent year over year.

The company posted sales of DKK30.1 million ($5.2 million) in the quarter ended Sept. 30, up from DKK27.1 million a year ago. Product sales totaled DKK20.7 million, up from DKK19.3 million a year ago. Service revenues were down slightly to DKK5.1 million from DKK5.3 million, and license-based revenues were up to DKK2.1 million from DKK1.2 million. Contract research revenues rose to DKK2.2 million from DKK1.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.